" class="no-js "lang="en-US"> Phio Pharmaceuticals Archives - Medtech Alert
Tuesday, May 28, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]

Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial to Treat Solid Tumors

Phio Pharmaceuticals has announced their clinical development partner, AgonOx, has received confirmation from the FDA […]

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals has announced it expects to file an IND in the US in the […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more